


Influence of time from admission to norepinephrine administration and volume of fluids received on outcomes of patients meeting sepsis-3 criteria: a retrospective study using the MIMIC-IV database

Tarek R Firzli,¹ Faria Z Miah ,¹ Cody Horton,¹ Hassan Akhtar,² Mark Riddle,¹ Faisal Siddiqui³

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/tsaco-2022-001024>).

¹University of Nevada Reno School of Medicine, Reno, Nevada, USA

²University of Nevada Reno, Reno, Nevada, USA

³Pulmonology and Critical Care, VA Sierra Nevada Health Care System, Reno, Nevada, USA

Correspondence to

Ms Faria Z Miah; fmiah@med.unr.edu

Received 4 October 2022

Accepted 11 February 2023

ABSTRACT

Objectives Vasopressors are a cornerstone in the management of sepsis, marked by distributive shock often unresponsive to fluid resuscitation. Prior research and clinician surveys have suggested that earlier usage of vasopressors corresponds to improved outcomes.

Methods A retrospective cohort was constructed using patient data contained within the Medical Information Mart for Intensive Care-IV database. Analytic cohort included a total of 2079 patients meeting sepsis-3 criteria with a ≥ 2 -point rise in Sequential Organ Failure Assessment score and administered norepinephrine (NE) as first-line vasopressor within 24 hours of admission to the intensive care unit (ICU). Patients receiving other vasopressors or missing documented fluid resuscitation information were excluded. Primary end points included mortality, use of invasive mechanical ventilation and length of stay which were analyzed in a multivariate logistic regression model for the primary effect of time from ICU admission to NE administration using covariates.

Results Time to NE use was defined as either early, using < 6 hours from time of ICU admission or late using > 6 hours to ≤ 24 hours. Patients who received early NE had significantly lower adjusted odds of mortality (0.75, 95% CI 0.57 to 0.97, $p=0.026$), higher adjusted odds of invasive mechanical ventilation (1.48, 95% CI 1.01 to 2.16, $p=0.045$), no significant difference in hospital length of stay (difference in days 0.6 (95% CI -3.24 to 2.04)) and lower ICU length of stay (difference in days -0.9 (95% CI -1.74 to -0.01)), as compared with the late NE group.

Conclusion Among patients admitted to the ICU for sepsis, early use of NE was associated with significantly lower odds of mortality but higher odds of mechanical ventilation, and no significant difference in length of hospital stay but less time in the ICU. Furthermore, the volume of fluids received prior to NE use may have a significant impact on optimal NE timing.

Level of evidence Level IV—therapeutic care/management.

INTRODUCTION

Sepsis is a common reason for intensive care unit (ICU) admission and a leading cause of death worldwide.^{1 2} Available literature suggests that sepsis accounts for $> 50\%$ of in-hospital mortality

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Early evidence, the Surviving Sepsis Campaign and physician practice surveys suggest that earlier use of vasopressors, even via peripheral lines may be optimal.
- ⇒ Although current practice and guidelines support this, there is no current specification of how much and when to administer them.

WHAT THIS STUDY ADDS

- ⇒ Using the Medical Information Mart for Intensive Care-IV database, this study is able to analyze the outcomes of early versus late norepinephrine administration and quantity of fluids during sepsis to better understand how much and when treatment should be initiated for patients.
- ⇒ This study adds to the building evidence that early administration of norepinephrine for sepsis reduces rates of mortality and length of hospital stay, irrespective of norepinephrine administration method or the amount of fluids given to patients.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ This study may add support to the importance of early norepinephrine use in patients with sepsis, help to guide sepsis protocols in hospitals and stimulate further research into the interaction between fluid use and vasopressor use.

annually, and those who survive develop long-term complications.^{3 4} Although mortality due to sepsis has steadily declined since 1991, its incidence has continued to rise and currently one-third of all ICU admissions are related to sepsis.⁵ This increasing incidence and prevalence of sepsis in US hospitals costs the healthcare system approximately US\$24 billion annually, making it the most expensive condition to treat in the US healthcare system.⁶

Sepsis is organ dysfunction secondary to a dysregulated inflammatory response to infection and is often defined as a 2-point increase in Sequential Organ Failure Assessment (SOFA) score, while septic shock is 'clinically identified by a vasopressor requirement to maintain a mean arterial pressure

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Firzli TR, Miah FZ, Horton C, *et al.* *Trauma Surg Acute Care Open* 2023;**8**:e001024.

(MAP) of 65 mm Hg or greater and serum lactate level >2 mmol/L in the absence of hypovolemia'.⁷ Early detection and initiation of treatment is crucial, as sepsis causes major systemic instability and rapid deterioration often leading to death.⁸ Thus, patients identified with sepsis in the emergency room have poorer outcomes when they are faced with prolonged wait times causing delay in transfer to the ICU and treatment. A study in 2001 targeted toward early goal-directed therapy (EGDT) of sepsis created a systemic approach to early management in the emergency department, thereby alleviating the negative impacts of prolonged wait times—this led to improved efforts in early recognition and management of sepsis.⁹ These early efforts are crucial in improving the odds of survival for these patients and follow-up trials after EGDT, including Protocolized Care for Early Septic Shock (PRoCESS), Australasian Resuscitation in Sepsis Evaluation (ARISE) and Protocolised Management in Sepsis (PRoMISe), demonstrated that mortality significantly improved in both the treatment and control arms.^{10–12} There is evidence that improved mortality is due to increased awareness of sepsis since the early 2000s and not necessarily the EGDT protocol.¹¹ This goal-directed management involving optimization of cardiac preload, afterload and contractility is currently used as the definitive resuscitation strategy in sepsis management.

As part of this strategy, patients are administered vasopressors to restore an adequate systemic vascular resistance that is often lacking in these 'warm' vasoplegic distributive shock patients. Current recommendations include starting vasopressors peripherally to restore MAP rather than waiting for a central venous access, and use of norepinephrine (NE) as a first-line agent.¹³ Delay in vasopressor initiation after 6 hours of sepsis detection is shown to increase 30-day mortality.¹⁴ Early NE administration to hypotensive patients with sepsis achieves target MAP earlier and decreases fluid overload which commonly complicates resuscitation efforts and hence decreases mortality rate.¹⁵

Although there are no definite guidelines for exact timing of initiation of vasopressor use with respect to time from admission or fluid status in septic shock patients, studies show early management of deteriorating MAP with vasopressors leads to better overall outcomes.¹⁴ This retrospective cohort study using a well-curated database aims to further analyze the outcomes of patients with septic shock who received early versus late treatment with NE and further to investigate the impact of the quantity of fluid resuscitation prior to NE administration on sepsis outcomes.

METHODS

This study was designed using retrospective cohort of patients with sepsis admitted to the ICU obtained from the Medical Information Mart for Intensive Care (MIMIC-IV), a freely available database of ICU stays from ICUs in the Beth Israel Deaconess Medical Center from 2008 to 2019 accessible via Physionet.¹⁶ From this database, patients were included in the analytic cohort if they were admitted with a sepsis diagnosis based on the sepsis-3 definition, demonstrated a rise in SOFA score of ≥ 2 points, and received NE within 24 hours of their ICU stay.⁷ Patients who received other vasopressor agents prior to NE (epinephrine, dopamine, vasopressin, dobutamine and phenylephrine), and subjects without data available on fluids received were excluded from the study.

Our primary end points included mortality, ICU length of stay and need for invasive mechanical ventilation (IMV) in patients who were not already intubated prior to NE administration. Our primary predictor variable was time from ICU admission to first

use of NE as measured in hours. A co-primary predictor variable was the volume of intravenous resuscitative fluids (normal saline, lactated ringers or colloid boluses) measured in kilograms per hour given prior to receiving NE. Additional covariates of age, ethnicity, comorbidities, risk scores (Acute Physiology Score [APSi], Simplified Acute Physiology Score [SAPSi], Sequential Organ Failure Assessment [SOFA], Oxford Acute Severity of Illness Score [OASIS]) were also selected for analysis. Furthermore, we included data on central versus peripheral line use for NE administration, rates of IMV and collected positive culture sources for cause of sepsis in each patient where these data were available. Patients were split into early vasopressor and late vasopressor groups based on a previously used cut-off of 6 hours from ICU admission to NE administration.

Univariate statistics were calculated for each variable between groups using the most appropriate statistical test (t-test for continuous normal variables, Mann-Whitney U test for non-normal continuous variables and Fisher's exact test for categorical variables). Those variables which significantly differed between groups (at a significance threshold of <0.1) were used as covariates in multivariate models evaluating early and late NE administration on each outcome (logistic regression for binary outcomes and linear regression for continuous outcomes).

We then split the cohort into groups based on quartiles of both fluids per kilogram per hour and for time to NE. We evaluated the effect of early and late NE use within these groups using multivariate models as in our primary analysis, including only covariates which differed significantly in univariate analysis. R-Studio V.4.1.2 and Jamovi V.2.3.21 was used for all statistical analysis and p values of <0.05 were considered statistically significant in our final multivariate model.^{17–21} Missing data were omitted listwise. No adjustments for multiple comparisons were made.

RESULTS

There were 13 515 patients who met the criteria for sepsis-3, received NE and had a ≥ 2 -point rise in SOFA score. After excluding patients who received pressors other than NE, patients who had missing fluid volume information and considering only patients receiving NE within 24 hours of ICU admission, a total of 2079 patients were available in the analytic cohort. The cohort was dichotomized based on a 6-hour cut-off from ICU admission to NE administration. The early NE group contained 1045 patients while the late NE group contained 1035 patients. Baseline characteristics were calculated between groups using the appropriate statistical tests. On univariate analysis, the following variables differed between groups ($p < 0.1$): rheumatic disease, first day SOFA score, OASIS score, APSi score, SAPSi score, first ICU stay, central line placement, mechanical ventilation prior to NE and fluids per kg per hour (table 1). For the primary outcomes analyzed in univariate analysis, the following outcomes were significantly different on univariate analysis ($p < 0.05$): mortality, IMV, ICU length of stay (table 1). Patients with the central lines had significantly lower mortality in the early NE group versus the late NE group (15.4% vs 21.7% $p = 0.0041$) and those without central lines had non-significantly lower mortality in the early NE group versus the late (14.4% vs 19.6% $p = 0.078$).

Positive culture data were collected for 779 patients among the entire cohort. The highest proportions of positive source cultures were obtained from blood (235 patients, 11.3%), sputum (162 patients, 7.8%) and urine (146 patients, 7.0%) (online supplemental table 1). Statistically significant differences were observed

Table 1 Baseline characteristics of early and late NE groups

		Late NE (n=1034)	Early NE (n=1045)	Total (n=2079)	P value
Age		66.1 (15.3)	65.5 (15.1)	65.8 (15.2)	0.3841
Ethnicity					0.4662
	American Indian/Alaska Native	4.0 (0.4%)	2.0 (0.2%)	6.0 (0.3%)	
	Asian	33.0 (3.2%)	27.0 (2.6%)	60.0 (2.9%)	
	Black/African-American	101.0 (9.8%)	107.0 (10.2%)	208.0 (10.0%)	
	Hispanic/Latino	37.0 (3.6%)	33.0 (3.2%)	70.0 (3.4%)	
	Other	36.0 (3.5%)	56.0 (5.4%)	92.0 (4.4%)	
	Unable to obtain	14.0 (1.4%)	15.0 (1.4%)	29.0 (1.4%)	
	Unknown	123.0 (11.9%)	111.0 (10.6%)	234.0 (11.3%)	
	White	686.0 (66.3%)	694.0 (66.4%)	1380.0 (66.4%)	
Male gender		591.0 (57.2%)	607.0 (58.1%)	1198.0 (57.6%)	0.6682
OASIS score		39.8 (9.1)	38.3 (9.1)	39.0 (9.1)	<0.001
ASPIII score		67.8 (26.0)	62.3 (24.1)	65.0 (25.2)	<0.001
SAPSII score		46.9 (14.8)	44.3 (14.1)	45.6 (14.5)	<0.001
SOFA score		9.9 (3.5)	9.5 (3.3)	9.7 (3.4)	0.0031
AIDS		15.0 (1.5%)	12.0 (1.1%)	27.0 (1.3%)	0.5432
CVD		134.0 (13.0%)	118.0 (11.3%)	252.0 (12.1%)	0.2442
COPD		306.0 (29.6%)	309.0 (29.6%)	615.0 (29.6%)	0.9902
CHF		353.0 (34.1%)	339.0 (32.4%)	692.0 (33.3%)	0.4112
Dementia		45.0 (4.4%)	53.0 (5.1%)	98.0 (4.7%)	0.4392
Diabetes with complication		125.0 (12.1%)	123.0 (11.8%)	248.0 (11.9%)	0.8232
Diabetes without complication		261.0 (25.2%)	265.0 (25.4%)	526.0 (25.3%)	0.9512
Malignant cancer		169.0 (16.3%)	169.0 (16.2%)	338.0 (16.3%)	0.9152
Metastatic solid tumor		69.0 (6.7%)	72.0 (6.9%)	141.0 (6.8%)	0.8442
Mild liver disease		212.0 (20.5%)	186.0 (17.8%)	398.0 (19.1%)	0.1172
MI		200.0 (19.3%)	202.0 (19.3%)	402.0 (19.3%)	0.9942
Paraplegia		46.0 (4.4%)	49.0 (4.7%)	95.0 (4.6%)	0.7932
Peptic ulcer disease		62.0 (6.0%)	56.0 (5.4%)	118.0 (5.7%)	0.5302
PVD		124.0 (12.0%)	137.0 (13.1%)	261.0 (12.6%)	0.4422
Renal disease		271.0 (26.2%)	268.0 (25.6%)	539.0 (25.9%)	0.7702
Rheumatic disease		45.0 (4.4%)	29.0 (2.8%)	74.0 (3.6%)	0.0522
Severe liver disease		119.0 (11.5%)	110.0 (10.5%)	229.0 (11.0%)	0.4742
Weight		82.3 (25.3)	81.9 (24.1)	82.1 (24.7)	0.7131
Central line		779.0 (77.3%)	553.0 (52.9%)	1352.0 (65.0%)	<0.001
First hospital admission		748.0 (72.3%)	738.0 (70.6%)	1486.0 (71.5%)	0.3862
First ICU admission		954.0 (92.3%)	959.0 (91.8%)	1913.0 (92.0%)	0.6792
Mechanical ventilation before NE		625.0 (60.4%)	540.0 (51.7%)	1165.0 (56.0%)	<0.001
Fluids received prior to NE		2218.6 (1885.5)	937.7 (1117.6)	1575.1 (1675.0)	<0.001
Fluids per kg per hour		2.5 (2.4)	8.3 (28.0)	5.4 (20.2)	<0.001
Fluids per kg		29.2 (26.5)	12.4 (15.6)	20.7 (23.3)	<0.001
Hospital LOS		16.2 (15.7)	16.8 (40.4)	16.5 (30.7)	0.6461
ICU LOS		6.8 (7.1)	5.9 (12.8)	6.4 (10.4)	0.0351
Mortality		219.0 (21.2%)	156.0 (14.9%)	375.0 (18.0%)	<0.001
Days until death		8.7 (7.2)	9.0 (7.2)	8.8 (7.2)	0.689
		Late NE (n=409)	Early NE (n=504)	Total (n=913)	P value
Mechanical ventilation after NE (IMV)		88.0 (21.5%)	145.0 (28.8%)	233.0 (25.5%)	0.0122
Mortality by NE administration route		Late NE (n=799)	Early NE (n=553)	Total (n=1352)	P value
	Central line	173.0 (21.7%)	85.0 (15.4%)	258.0 (19.1%)	0.0041
		Late NE (n=235)	Early NE (n=492)	Total (n=727)	P value
	Peripheral line	46.0 (19.6%)	71.0 (14.4%)	117.0 (16.1%)	0.0781

CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; ICU, intensive care unit; IMV, invasive mechanical ventilation; LOS, length of stay; MI, myocardial infarction; NE, norepinephrine; PVD, peripheral vascular disease; SOFA, Sequential Organ Failure Assessment.

CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; ICU, intensive care unit; IMV, invasive mechanical ventilation; LOS, length of stay; MI, myocardial infarction; NE, norepinephrine; PVD, peripheral vascular disease; SOFA, Sequential Organ Failure Assessment.

between early and late NE groups for the following cultures: urine (5.7% vs 8.3% $p=0.022$), tissue (0.5% vs 1.4% $p=0.036$), blood (13.1% vs 9.5% $p=0.0091$) and *Staphylococcus aureus* screen (0.1% vs 0.7% $p=0.032$) (online supplemental table 1).

Multivariate logistic regression showed that patients in the early NE group had 0.75 (95% CI 0.57 to 0.97) (reported

as OR, OR with 95% CI) times decreased risk of 28 days in hospital mortality (table 2, figure 1) and 1.48 (95% CI 1.01 to 2.16) (OR) times increased risk of requiring IMV among patients who were not already requiring IMV (table 2, figure 2). Patients in the early NE group had no significant difference in hospital length of stay (difference in days 0.6 (95% CI -3.24 to 2.04))

Table 2 Early versus late NE association with outcomes in multivariable logistic regression or linear regression models

Outcome	Adjusted OR or standard estimate	95% CI	P value
Mortality (OR)	0.75	0.57 to 0.97	0.026
Mechanical ventilation (OR)	1.48	1.01 to 2.16	0.045
Hospital LOS (SE)	0.02	−0.03 to 0.064	0.40
ICU LOS (SE)	−0.03	−0.08 to 0.01	0.15


ICU, intensive care unit; LOS, length of stay; NE, norepinephrine.

(table 2, figure 3) and lower ICU length of stay (difference in days -0.9 (95% CI -1.74 to -0.01)) (table 2, figure 4).

Patients were then placed into quartile groups based on the volume of fluids received per kilogram per hour prior to NE administration. Quartile 1 consisted of patients receiving <0.815 mL/kg/hour, quartile 2 consisted of patients receiving between 0.815 mL/kg/hour and 2.334 mL/kg/hour, quartile 3 consisted of patients receiving between 2.334 mL/kg/hour and 5.075 mL/kg/hour and quartile 4 consisted of patients receiving >5.075 mL/kg/hour of fluids. For each group, multivariate logistic regression or linear regression was used to assess the effect of early versus late vasopressor use on primary outcomes. Figure 5 shows that there was no statistically significant difference in mortality in

any of these fluid quartiles, however in quartiles 1, 2 and 4 the ORs were 0.864 , 0.689 and 0.854 , respectively while in quartile 3 the odds of mortality was 1.201 . Patients in quartiles 1 and 2 of fluids had significantly higher odds of IMV (2.687 (95% CI 1.402 to 5.149) and 2.852 (95% CI 1.412 to 5.759)) while in quartiles 3 and 4 there were increased odds of IMV which was not statistically significant (1.337 and 1.447). Patients in quartile 1 in the early NE group had significantly lower hospital length of stays (difference in days -4.9 (95% CI -7.80 to -0.99)) while in all other quadrants, there were no statistically significant differences in hospital length of stay, although ICU and hospital length of stays were higher. Patients in quartile 2 in the early NE group had significantly lower ICU length of stays (difference in days -1.70 (95% CI -2.82 to -0.58)) while in other groups there were lower ICU length of stays which did not reach statistical significance (figure 5). Additional outcomes as well as characteristics of patients in each quartile may be found in online supplemental tables 2–9.

To further explore the effect of NE timing and volumes received, the cohort was further grouped into quartiles of minutes from ICU admission to NE administration as well as quartiles of fluid volume per kilogram per hour. Mortality was calculated within each time and fluid quartile, shown in figure 6. Mortality tended to be lowest in the patients who received high volumes of fluids and NE earlier. Mortality appeared highest in those receiving lower volumes of fluids, but with later NE usage.

**Figure 1** Adjusted ORs of 28-day mortality logistic regression model covariates. NE, norepinephrine; SOFA, Sequential Organ Failure Assessment.




Figure 2 Adjusted ORs of invasive mechanical ventilation logistic regression model covariates. NE, norepinephrine; SOFA, Sequential Organ Failure Assessment.

This analysis also demonstrated that the lowest mortality overall occurred within the patients with the earliest NE use (<152 min), while the highest mortality occurred in patients with the latest NE use (701–1437 min).

DISCUSSION

The Surviving Sepsis Campaign guideline compilation produced by the Society of Critical Care Medicine aligns with the findings of this study, recommending the early use of vasoactive agents to support MAP without any specific time guidelines.¹³ However, in 2018, a new updated 1-hour bundle suggested starting vasopressors after initial fluid resuscitation if unresponsive to initial fluids.²² In particular, the use of NE as the first-line vasopressor is highly recommended, as well as the possible addition of other agents depending on the response and status of the patient in the most recent guidelines.¹³ Generally, there is some consensus among clinicians that earlier use of vasopressors, after initial fluid resuscitation or before completion of fluid resuscitation is optimal.²³ This is likely due in part to the decreased risk of fluid overload and increased vascular permeability, which may decrease organ damage and the incidence of procedures such as thoracentesis, paracentesis and diuretic use which come with increased risk to the patient.^{24–25} There is limited evidence to support the ideal window for initiating vasopressor administration in the setting of septic shock, thus the decision to begin using NE is mostly guided by a high clinical suspicion for further

deterioration despite aggressive fluid resuscitation, signs and symptoms of tissue malperfusion and thorough consideration of any coexisting risk factors or comorbidities. Given this, it is difficult to establish clear factors to determine the optimal time for initiation of NE or vasopressor support.

Guidelines do not specify the timing and volume of fluid resuscitation and initiation of vasopressor use. To our knowledge, only one study has investigated the interaction between fluids received and vasoactive agent use. This study suggested that at least 1 L of fluids prior to vasopressor use was associated with lower mortality.²⁶ Additionally, studies have also suggested that negative fluid balance is associated with decreased mortality.^{27–28} Sepsis is not primarily a volume depleted state and thus many patients with sepsis are not responsive to fluids.²⁹ Many patients are however volume resuscitated without assessment of responsiveness which can lead to delay in the administration of vasopressors needed to increase MAP.

In our analysis, we found that patients receiving early NE had significantly lower mortality and ICU length of stay than those who received late NE but the need for mechanical ventilation was higher. This result aligns with several other smaller studies and trials which show that early NE improves overall outcomes.^{15–30–32} Importantly, the mortality benefit was controlling for several important factors which differed between groups. Multiple risk stratification scores including SOFA score, APSii, SAPSii and OASIS were significantly higher in the late NE




Figure 3 Standardized estimate of hospital length of stay linear regression model covariates. NE, norepinephrine; SOFA, Sequential Organ Failure Assessment.

group and thus were included in our final model. Additionally, we saw that significantly fewer patients in the early NE group (52.9% vs 77.3%) had invasive intravenous lines placed prior to NE being administered and significantly fewer patients in the early group were mechanically ventilated prior to NE (51.7% vs 60.4% $p<0.001$). We found that in univariate analysis, lower mortality was observed in patients receiving early versus late NE via a central line while there was a lower mortality without quite reaching significance in patients receiving early versus late NE via a peripheral line (14.4% vs 19.6% $p=0.078$). This factor was included in our multivariate model, and suggests that the potential mortality benefit remains after controlling for peripheral versus central line administration of NE. This result aligns with current recommendations that peripheral vasopressor usage is appropriate in the correct clinical setting in order to prevent delay of vasopressor administration. In the analysis of mechanical ventilation, we excluded patients who were already ventilated by the time NE was started. In the late NE group, 625 patients (60.4%) were already intubated, while in the early NE group, 540 patients (51.7%) were intubated. Among all patients irrespective of NE timing, 685 in the early NE group (65.56%) and 713 in the late NE group (68.96%) were intubated. Although more patients in the late group were intubated overall, the fact that they had more time from admission to NE administration likely played a role in their requirement for intubation. Overall, it appears that the increased time between admission and delay

in NE use increased the window for patients to require ventilatory support.

Culture data suggested that the highest proportions of positive cultures were from blood, sputum and urine cultures. This could suggest that the most common etiologies of sepsis in this cohort were bacteremia, pneumonia and urinary tract infections. There were more positive blood cultures in the early NE group and fewer positive urine cultures when compared with late NE group suggesting a higher proportion of bacteremic patients compared with patients with urosepsis. As blood cultures are in the initial sepsis bundles and urine cultures are not, this could explain in part why patients got earlier NE treatment, however this is very limited in that we only were able to obtain positive culture results in 779 patients of our total cohort. This information thus was not included in our final model, however we support further investigation into this explanation.

Literature has previously suggested that there may be an optimal fluid volume of resuscitation prior to using vasoactive agents.²⁶ Our study suggests the opposite, that receiving vasoactive agents such as NE earlier in their ICU stay regardless of the amount of fluids received has a positive impact on mortality. Overall, we saw no statistically significant differences in these subgroups which could point to mediation of our observed decrease in mortality with early NE use based on the quantity of fluids received. We did observe a non-significant increase in mortality among patients with fluid use of 2.334–5.075 mL/




Figure 4 Standardized estimate of ICU length of stay linear regression model covariates. ICU, intensive care unit; NE, norepinephrine; SOFA, Sequential Organ Failure Assessment.

kg/hour, however this trend did not remain in those receiving >5.075 mL/kg/hour. The odds of requiring mechanical ventilation after NE was increased in some cases, likely due to the timeframe where intubation could be required was ≤ 6 hours in the early group and up to 24 hours in the late NE group, therefore more of the late NE patients were excluded as more already were mechanically ventilated. This may suggest that NE timing does not have a significant effect on mechanical ventilation needs, which may be more of a function of the source of sepsis and pre-existing pulmonary pathologies. The difficulty in assessing this variable given that timeframes in which mechanical ventilation could be required is significantly different between groups indicating that more research focused on this primary outcome would likely be needed in a prospective design. No notable trends were demonstrated in length of stay based on fluid quartiles that differed from our main results. In sum, it did not appear that fluids received had significant effects on our main outcomes, and that the early use of NE had a greater impact on mortality in patients meeting sepsis-3 criteria and did not appear to be mediated in large part by fluid quantity.

We further investigated the interaction between fluid volume received and time to NE use on mortality in a more granular way. This revealed that in general, lower times to NE use were associated with lower mortality, regardless of fluid amount received. In figure 6, the bottom right quadrant shows patients with higher fluid use as well as lower time to NE resulting in

lower mortality than those in the top left quadrant, who were given lower volumes of fluid use and higher time to NE. When comparing the bottom left quadrant where patients received lower fluid volumes and had less time before NE to the top right quadrant where patients received higher fluid volumes and had more time before NE, it appeared that NE timing may have a more significant impact on mortality than fluids. Current fluid resuscitation guidelines recommend 30 cc/kg as an initial fluid bolus. Using these data, we can infer that patients in certain quadrants received <30 cc/kg or >30 cc/kg as an initial fluid bolus, but cannot make a direct comparison as many patients had multiple boluses given over different time periods. Therefore, a possible strategy may be using NE very early (quartile 1) irrespective of fluid use, but giving adequate amounts of fluids may become more beneficial to outcomes when vasopressors are administered late. It is important to note that this analysis was not controlling for other covariates, and does not consider time over which boluses were administered, nor the number of total boluses received.

The determination of adequate response and achievement of fluid resuscitation is another component of sepsis management that requires the insight and clinical supervision of a physician. This distinction is not made lightly and depends on thorough review of patients' vitals, labs, physical exam with an emphasis on volume status and thoughtful consideration of coexisting conditions and comorbidities. Future studies may be aimed at




Figure 5 Outcomes in late versus early NE groups by multivariate logistic or linear regression, stratified by total volume of fluids per kg per hour given before vasopressors, expressed as quartile groups. ICU, intensive care unit; NE, norepinephrine.




Figure 6 Mortality heat map based on quartiles of fluids received prior to vasopressors and quartiles of time from admission to vasopressor administration. NE, norepinephrine.

determining the most important indicators of adequate fluid resuscitation with respect to patients with sepsis and the etiology of their source of sepsis, however this particular topic was outside of the scope of this study.

We note several important limitations to this study. The retrospective nature of the study, which prevents inferences of causality and the single center data source limits generalizability. This database may also contain incomplete or inaccurate information secondary to inaccurate charting of real-time events. This required us to exclude patients from the analysis where we lacked information on fluid boluses or vasopressor use which may impact the generalizability or accuracy of our results. We were not able to obtain sufficient information regarding culture data, or source control to make conclusions or to control for sepsis sources in our cohorts. Lastly, we did not have access to cause of death information and thus were limited to all cause in-hospital 28-day mortality as our primary outcome of interest. Despite these limitations, this well-known clinical database provides a large sample size and numerous comorbidity variables, as well as risk stratification scores which allow for increased control of potential confounding factors. We believe this strengthens our interpretation of these observed associations.

Future research on this topic could clarify several aspects which we did not address. Although fluid volume per kilogram per hour seemed a reasonable way to quantify fluids in patients of differing weights and who were admitted for different periods of time, it is an imperfect measure given that resuscitation fluid boluses are often given at irregular intervals in response to blood pressure. Furthermore, we do not know of the initial fluid status of patients in this study. We suggest that measures such as ultrasound assessment of fluid responsiveness or even central venous pressure should be used in future research.³³ Randomized clinical trials with differing fluid guidelines are likely needed, however care must be taken to ensure patient safety in the design as serious consequences could result from high or low deviations from typical fluid use.

CONCLUSION

Our research adds to the building evidence in favor of early use of vasoactive compounds (primarily NE) in severe sepsis and septic shock. We cannot conclude causation of the lowered mortality, nor the optimal timing of vasoactive agent usage. In this cohort however, lower 28-day mortality was associated with NE use within 6 hours of ICU admission for sepsis and septic shock as defined by sepsis-3 criteria, as well as a >2-point increase in SOFA score. We further found that early NE use was associated with decreased mortality compared with later NE and that this effect did not appear to be mediated by volume of fluids received. Although on univariate subgroup analysis, patients receiving early NE via central line reached statistical significance and patients with peripheral administration did not, in both cases mortality was lower in the early NE group, and this factor was controlled for in our multivariate model. We suggest that the association between early NE use and mortality remains in spite of the route of administration of NE, in line with current recommendations. NE administration did not appear associated with ICU or hospital length of stay in our multivariate model, while the patients in the early group had higher rates of mechanical ventilation after NE use, which may be attributed to the fact that far fewer patients were mechanically ventilated prior to NE use compared with the late group. We support additional research to elucidate the optimal balance between fluids and vasopressors in sepsis.

Contributors TRF, FZM and CH contributed equally to this paper. TRF:

conceptualization and study design, data access, data analysis, data interpretation, manuscript writing and submission. FZM: conceptualization and study design, data interpretation, manuscript writing and submission. CH: conceptualization and study design, data interpretation, manuscript writing. HA: figures and tables. MR: conceptualization, study design, data access and supervision. FS: the guarantor of the paper, responsible for the conceptualization, data interpretation, manuscript writing, and oversight of the project as supervising author.

Funding Funding for open access publication was provided by the University of Nevada, Reno School of Medicine Open Access Fund

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Faria Z Miah <http://orcid.org/0000-0002-7093-5907>

REFERENCES

- 1 Vincent J-L, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, Reinhart K, Antonelli M, Pickkers P, Njimi H, *et al.* Assessment of the worldwide burden of critical illness: the intensive care over nations (icon) audit. *Lancet Respir Med* 2014;2:380–6.
- 2 Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-Loeches I, Leone M, Lupu MN, Vincent JL, *et al.* Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. *Open Forum Infect Dis* 2018;5:ofy313.
- 3 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303–10.
- 4 Mostel Z, Perl A, Marck M, Mehdi SF, Lowell B, Bathija S, Santosh R, Pavlov VA, Chavan SS, Roth J. Post-sepsis syndrome - an evolving entity that afflicts survivors of sepsis. *Mol Med* 2019;26:6.
- 5 Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall J-R, Payen D, *et al.* Sepsis in European intensive care units: results of the soap study. *Crit Care Med* 2006;34:344–53.
- 6 Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and costs of sepsis in the united states-an analysis based on timing of diagnosis and severity level. *Crit Care Med* 2018;46:1889–97.
- 7 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, *et al.* The third International consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 2016;315:801–10.
- 8 Font MD, Thyagarajan B, Khanna AK. Sepsis and septic shock - basics of diagnosis, pathophysiology and clinical decision making. *Med Clin North Am* 2020;104:573–85.
- 9 Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368–77.
- 10 Investigators P, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, *et al.* A randomized trial of protocol-based care for early septic shock. *N Engl J Med* 2014;370:1683–93.
- 11 ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, *et al.* Goal-Directed resuscitation for patients with early septic shock. *N Engl J Med* 2014;371:1496–506.

- 12 Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, *et al.* Trial of early, goal-directed resuscitation for septic shock. *N Engl J Med* 2015;372:1301–11.
- 13 Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, *et al.* Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Crit Care Med* 2021;49:e1063–143.
- 14 Colon Hidalgo D, Patel J, Masic D, Park D, Rech MA. Delayed vasopressor initiation is associated with increased mortality in patients with septic shock. *J Crit Care* 2020;55:145–8.
- 15 Li Y, Li H, Zhang D. Timing of norepinephrine initiation in patients with septic shock: a systematic review and meta-analysis. *Crit Care* 2020;24:488.
- 16 Johnson A, Bulgarelli L, Pollard T, Horng S, Celi LA, Mark Roger. MIMIC-IV [internet]. physionet. Available: <https://physionet.org/content/mimiciv/0.4/>
- 17 The jamovi project. jamovi. (Version 2.3) [Computer Software]. 2022. Available: <https://www.jamovi.org>
- 18 R Core TeamR: A Language and environment for statistical computing. (Version 4.1) [Computer software]. 2021. Available: <https://cran.r-project.org>
- 19 Garbett S. tangram: The Grammar of Tables. [R package]. 2018. Available: <https://CRAN.R-project.org/package=tangram>
- 20 Serdar BalciClinicoPath jamovi Module doi:10.5281/zenodo.3997188. [R package]. 2022. 10.5281/zenodo.3997188
- 21 RStudio Team. RStudio: integrated development for R. 2021. Available: <http://www.rstudio.com/>
- 22 Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. *Crit Care Med* 2018;46:997–1000.
- 23 Shi R, Hamzaoui O, De Vita N, Monnet X, Teboul JL. Vasopressors in septic shock: which, when, and how much? *Ann Transl Med* 2020;8:794.
- 24 Kelm DJ, Perrin JT, Cartin-Ceba R, Gajic O, Schenck L, Kennedy CC. Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. *Shock* 2015;43:68–73.
- 25 Malbrain MLNG, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, Van Regenmortel N. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. *Anaesthesiol Intensive Ther* 2014;46:361–80.
- 26 Waechter J, Kumar A, Lapinsky SE, Marshall J, Dodek P, Arabi Y, Parrillo JE, Dellinger RP, Garland A, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Interaction between fluids and vasoactive agents on mortality in septic shock: a multicenter, observational study. *Crit Care Med* 2014;42:2158–68.
- 27 Wang YM, Chen Y, Zheng YJ, Huang YC, Chen WW, Ji R, Xu LL, Yang ZT, Sheng HQ, Qu HP, *et al.* Low fluid intake volume during the first 24 H and persistent negative fluid balance from the second day are associated with favorable prognosis for patients with sepsis. *Exp Ther Med* 2021;21:387.
- 28 Pittard MG, Huang SJ, McLean AS, Orde SR. Association of positive fluid balance and mortality in sepsis and septic shock in an Australian cohort. *Anaesth Intensive Care* 2017;45:737–43.
- 29 Marik P, Bellomo R. A rational approach to fluid therapy in sepsis. *Br J Anaesth* 2016;116:339–49.
- 30 Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. *Am J Respir Crit Care Med* 2019;199:1097–105.
- 31 Elbouhy MA, Soliman M, Gaber A, Taema KM, Abdel-Aziz A. Early use of norepinephrine improves survival in septic shock: earlier than early. *Arch Med Res* 2019;50:325–32.
- 32 Ospina-Tascón GA, Hernandez G, Alvarez I, Calderón-Tapia LE, Manzano-Nunez R, Sánchez-Ortiz AI, Quiñones E, Ruiz-Yucuma JE, Aldana JL, Teboul J-L, *et al.* Effects of very early start of norepinephrine in patients with septic shock: a propensity score-based analysis. *Crit Care* 2020;24:52.
- 33 Chaudhuri D, Herritt B, Lewis K, Diaz-Gomez JL, Fox-Robichaud A, Ball I, Granton J, Rochwerf B. Dosing fluids in early septic shock. *Chest* 2021;159:1493–502.

Supplemental Materials

Supplemental Table 1: Positive culture sources by Early and Late NE cohorts

	Late NE (N=1034)	Early NE (N=1045)	Total (N=2079)	p value
Staph aureus Screen	7.0 (0.7%)	1.0 (0.1%)	8.0 (0.4%)	0.0321
SWAB	21.0 (2.0%)	21.0 (2.0%)	42.0 (2.0%)	0.9721
URINE	86.0 (8.3%)	60.0 (5.7%)	146.0 (7.0%)	0.0221
BRONCHOALVEOLAR LAVAGE	40.0 (3.9%)	30.0 (2.9%)	70.0 (3.4%)	0.2071
STOOL	15.0 (1.5%)	13.0 (1.2%)	28.0 (1.3%)	0.6831
TISSUE	14.0 (1.4%)	5.0 (0.5%)	19.0 (0.9%)	0.0361
PERITONEAL FLUID	4.0 (0.4%)	2.0 (0.2%)	6.0 (0.3%)	0.4061
ABSCCESS	4.0 (0.4%)	3.0 (0.3%)	7.0 (0.3%)	0.6951
MRSA SCREEN	15.0 (1.5%)	8.0 (0.8%)	23.0 (1.1%)	0.1351
CATHETER OR LINE	3.0 (0.3%)	1.0 (0.1%)	4.0 (0.2%)	0.3121
SPUTUM	88.0 (8.5%)	74.0 (7.1%)	162.0 (7.8%)	0.2241
BRONCHIAL WASHINGS	8.0 (0.8%)	7.0 (0.7%)	15.0 (0.7%)	0.7801
BLOOD	98.0 (9.5%)	137.0 (13.1%)	235.0 (11.3%)	0.0091
BILE	4.0 (0.4%)	1.0 (0.1%)	5.0 (0.2%)	0.1751
FOOT CULTURE	1.0 (0.1%)	0.0 (0.0%)	1.0 (0.0%)	0.3151
PLEURAL FLUID	3.0 (0.3%)	1.0 (0.1%)	4.0 (0.2%)	0.3121
FOREIGN BODY	1.0 (0.1%)	0.0 (0.0%)	1.0 (0.0%)	0.3151
EAR	1.0 (0.1%)	0.0 (0.0%)	1.0 (0.0%)	0.3151
Isolate	0.0 (0.0%)	1.0 (0.1%)	1.0 (0.0%)	0.3201
TRACHEAL ASPIRATE	0.0 (0.0%)	1.0 (0.1%)	1.0 (0.0%)	0.3201

Supplemental Table 2: Characteristics of Early and Late NE Groups in Patients Receiving Quartile 1 of Fluids (<0.815mL/kg*hr)

		Late NE (N=263)	Early NE (N=258)	Total (N=521)	p value
Age		65.8 (14.2)	65.5 (14.1)	65.7 (14.1)	0.8481
Ethnicity					0.8102
	AMERICAN INDIAN/ALASKA NATIVE	1.0 (0.4%)	1.0 (0.4%)	2.0 (0.4%)	
	ASIAN	6.0 (2.3%)	5.0 (1.9%)	11.0 (2.1%)	
	BLACK/AFRICAN AMERICAN	27.0 (10.3%)	38.0 (14.7%)	65.0 (12.5%)	
	HISPANIC/LATINO	11.0 (4.2%)	7.0 (2.7%)	18.0 (3.5%)	
	OTHER	7.0 (2.7%)	8.0 (3.1%)	15.0 (2.9%)	
	UNABLE TO OBTAIN	2.0 (0.8%)	1.0 (0.4%)	3.0 (0.6%)	
	UNKNOWN	31.0 (11.8%)	26.0 (10.1%)	57.0 (10.9%)	
	WHITE	178.0 (67.7%)	172.0 (66.7%)	350.0 (67.2%)	
Male Gender		146.0 (55.5%)	148.0 (57.4%)	294.0 (56.4%)	0.6702
OASIS Score		39.2 (9.2)	38.7 (8.5)	39.0 (8.8)	0.4941
APSIi Score		65.6 (24.7)	60.1 (23.3)	62.9 (24.1)	0.0091
SAPSi Score		45.9 (14.3)	44.0 (12.8)	45.0 (13.6)	0.1081
SOFA Score		10.3 (3.5)	10.0 (3.1)	10.2 (3.3)	0.1941
AIDS		1.0 (0.4%)	3.0 (1.2%)	4.0 (0.8%)	0.3062
CVD		36.0 (13.7%)	41.0 (15.9%)	77.0 (14.8%)	0.4792
COPD		78.0 (29.7%)	80.0 (31.0%)	158.0 (30.3%)	0.7382
CHF		132.0 (50.2%)	94.0 (36.4%)	226.0 (43.4%)	0.0022
Dementia		7.0 (2.7%)	11.0 (4.3%)	18.0 (3.5%)	0.3172
Diabetes with Complication		46.0 (17.5%)	44.0 (17.1%)	90.0 (17.3%)	0.8952
Diabetes without Complication		82.0 (31.2%)	76.0 (29.5%)	158.0 (30.3%)	0.6692
Malignant Cancer		40.0 (15.2%)	38.0 (14.7%)	78.0 (15.0%)	0.8782
Metastatic Solid Tumor		13.0 (4.9%)	20.0 (7.8%)	33.0 (6.3%)	0.1882
Mild Liver Disease		65.0 (24.7%)	56.0 (21.7%)	121.0 (23.2%)	0.4162
MI		62.0 (23.6%)	54.0 (20.9%)	116.0 (22.3%)	0.4682
Paraplegia		9.0 (3.4%)	18.0 (7.0%)	27.0 (5.2%)	0.0672
Peptic Ulcer Disease		17.0 (6.5%)	13.0 (5.0%)	30.0 (5.8%)	0.4852
PVD		39.0 (14.8%)	26.0 (10.1%)	65.0 (12.5%)	0.1012
Renal Disease		93.0 (35.4%)	68.0 (26.4%)	161.0 (30.9%)	0.0262
Rheumatic Disease		9.0 (3.4%)	4.0 (1.6%)	13.0 (2.5%)	0.1712
Severe Liver Disease		49.0 (18.6%)	36.0 (14.0%)	85.0 (16.3%)	0.1492
Weight		88.7 (29.1)	84.7 (25.2)	86.7 (27.3)	0.0901
Central Line		197.0 (74.9%)	141.0 (54.7%)	338.0 (64.9%)	< 0.001 ¹
First Hospital Admission		188.0 (71.5%)	180.0 (69.8%)	368.0 (70.6%)	0.6672
First ICU Admission		242.0 (92.0%)	247.0 (95.7%)	489.0 (93.9%)	0.0772
Mechanically Ventilated Prior to NE		159.0 (60.5%)	165.0 (64.0%)	324.0 (62.2%)	0.4102
Hospital LOS		18.5 (19.7)	13.6 (13.4)	16.1 (17.0)	< 0.001 ¹
ICU LOS		7.5 (8.3)	6.1 (6.1)	6.8 (7.3)	0.0341
Mortality		69.0 (26.2%)	45.0 (17.4%)	114.0 (21.9%)	0.0152
Total Fluids prior to NE		435.8 (381.2)	62.8 (82.8)	251.1 (333.9)	< 0.001 ¹
Fluids per Kg per Hour		0.4 (0.2)	0.3 (0.2)	0.3 (0.2)	< 0.001 ¹
Fluids per Kg		5.0 (4.1)	0.7 (0.9)	2.9 (3.7)	< 0.001 ¹
		0 (N=104)	1 (N=93)	Total (N=197)	p value
Mechanical Ventilation After NE		29.0 (27.9%)	44.0 (47.3%)	73.0 (37.1%)	0.0052

Supplemental Table 3: Outcomes in Early and Late NE Groups within Quartile 1

Predictor	Estimate	SE	Z	p	Odds Ratio or Standardized Estimate	Lower	Upper
Mortality	-0.349	0.246	-1.417	0.156	0.706	0.435	1.143
Mechanical Ventilation	0.988	0.332	2.979	0.003	2.687	1.402	5.149
Hospital LOS	-3.715	1.495	-2.485	0.013	-0.218	-0.391	-0.046
ICU LOS	-0.804	0.634	-1.268	0.205	-0.11	-0.28	0.06

Supplemental Table 4: Characteristics of Early and Late NE Groups in Patients Receiving Quartile 2 of Fluids (0.815-2.334 mL/kg*hr)

		Late NE (N=347)	Early NE (N=172)	Total (N=519)	p value
Age		65.9 (15.8)	65.4 (14.3)	65.7 (15.3)	0.7051
Ethnicity					0.3552
	AMERICAN INDIAN/ALASKA NATIVE	1.0 (0.3%)	1.0 (0.6%)	2.0 (0.4%)	
	ASIAN	11.0 (3.2%)	3.0 (1.7%)	14.0 (2.7%)	
	BLACK/AFRICAN AMERICAN	33.0 (9.5%)	14.0 (8.1%)	47.0 (9.1%)	
	HISPANIC/LATINO	9.0 (2.6%)	5.0 (2.9%)	14.0 (2.7%)	
	OTHER	11.0 (3.2%)	11.0 (6.4%)	22.0 (4.2%)	
	UNABLE TO OBTAIN	4.0 (1.2%)	4.0 (2.3%)	8.0 (1.5%)	
	UNKNOWN	50.0 (14.4%)	16.0 (9.3%)	66.0 (12.7%)	
	WHITE	228.0 (65.7%)	118.0 (68.6%)	346.0 (66.7%)	
Male Gender		210.0 (60.5%)	95.0 (55.2%)	305.0 (58.8%)	0.2492
OASIS Score		40.2 (9.2)	39.2 (8.5)	39.9 (9.0)	0.2121
APSi Score		69.9 (25.5)	64.9 (23.9)	68.2 (25.0)	0.0341
SAPSi Score		47.6 (14.9)	45.4 (14.4)	46.9 (14.8)	0.1091
SOFA Score		10.1 (3.7)	9.9 (3.5)	10.1 (3.6)	0.5181
AIDS		5.0 (1.4%)	1.0 (0.6%)	6.0 (1.2%)	0.3892
CVD		52.0 (15.0%)	11.0 (6.4%)	63.0 (12.1%)	0.0052
COPD		105.0 (30.3%)	59.0 (34.3%)	164.0 (31.6%)	0.3512
CHF		124.0 (35.7%)	73.0 (42.4%)	197.0 (38.0%)	0.1382
Dementia		18.0 (5.2%)	9.0 (5.2%)	27.0 (5.2%)	0.9832
Diabetes with CC		46.0 (13.3%)	13.0 (7.6%)	59.0 (11.4%)	0.0542
Diabetes without CC		97.0 (28.0%)	46.0 (26.7%)	143.0 (27.6%)	0.7722
Malignant CA		45.0 (13.0%)	28.0 (16.3%)	73.0 (14.1%)	0.3072
Metastatic Solid Tumor		17.0 (4.9%)	5.0 (2.9%)	22.0 (4.2%)	0.2892
Mild Liver Disease		78.0 (22.5%)	42.0 (24.4%)	120.0 (23.1%)	0.6222
MI		75.0 (21.6%)	36.0 (20.9%)	111.0 (21.4%)	0.8582
Paraplegia		13.0 (3.7%)	2.0 (1.2%)	15.0 (2.9%)	0.0982
Peptic Ulcer Disease		22.0 (6.3%)	8.0 (4.7%)	30.0 (5.8%)	0.4382
PVD		38.0 (11.0%)	28.0 (16.3%)	66.0 (12.7%)	0.0862
Renal Disease		94.0 (27.1%)	50.0 (29.1%)	144.0 (27.7%)	0.6352
Rheumatic Disease		16.0 (4.6%)	5.0 (2.9%)	21.0 (4.0%)	0.3542
Severe Liver Disease		44.0 (12.7%)	24.0 (14.0%)	68.0 (13.1%)	0.6862
Weight		85.6 (25.2)	87.9 (28.2)	86.4 (26.2)	0.3381
Central Line		259.0 (74.6%)	95.0 (55.2%)	354.0 (68.2%)	< 0.001 [†]
First Hospital Admission		256.0 (73.8%)	117.0 (68.0%)	373.0 (71.9%)	0.1702
First ICU Admission		313.0 (90.2%)	155.0 (90.1%)	468.0 (90.2%)	0.9752
Hospital LOS		15.9 (13.7)	16.6 (20.0)	16.1 (16.0)	0.6511
ICU LOS		6.8 (6.9)	5.1 (4.2)	6.3 (6.2)	0.0031
Mortality		94.0 (27.1%)	33.0 (19.2%)	127.0 (24.5%)	0.0492
Mechanically Ventilated Prior to NE		212.0 (61.1%)	90.0 (52.3%)	302.0 (58.2%)	0.0572
Total Fluids		1654.4 (876.0)	429.0 (305.1)	1248.3 (936.3)	< 0.001 [†]
Fluids per Kg per Hour		1.5 (0.5)	1.6 (0.4)	1.5 (0.4)	0.2881
Fluids per Kg		19.7 (9.2)	4.9 (2.9)	14.8 (10.4)	< 0.001 [†]
		Late NE (N=135)	Early NE (N=82)	Total (N=217)	p value
Mechanical Ventilation after NE		25.0 (18.5%)	29.0 (35.4%)	54.0 (24.9%)	0.0052

Supplemental Table 5: Outcomes in Early and Late NE Groups within Quartile 2

Predictor	Estimate	SE	Z	p	Odds Ratio or Standardized Estimate	Lower	Upper
Mortality	-0.293	0.26	-1.127	0.26	0.746	0.448	1.242
Mechanical Ventilation	1.048	0.359	2.923	0.003	2.852	1.412	5.759
Hospital LOS	1.342	1.551	0.865	0.387	0.039	-0.05	0.129
ICU LOS	-1.254	0.558	-2.247	0.025	-0.096	-0.179	-0.012

Supplemental Table 6: Characteristics of Early and Late NE Groups in Patients Receiving Quartile 3 of Fluids (2.334-5.075 mL/kg*hr)

		Late NE (N=290)	Early NE (N=231)	Total (N=521)	p value
Age		66.2 (15.3)	65.6 (15.1)	66.0 (15.2)	0.6471
Ethnicity					0.8072
	AMERICAN INDIAN/ALASKA NATIVE	2.0 (0.7%)	0.0 (0.0%)	2.0 (0.4%)	
	ASIAN	7.0 (2.4%)	4.0 (1.7%)	11.0 (2.1%)	
	BLACK/AFRICAN AMERICAN	30.0 (10.3%)	21.0 (9.1%)	51.0 (9.8%)	
	HISPANIC/LATINO	10.0 (3.4%)	11.0 (4.8%)	21.0 (4.0%)	
	OTHER	13.0 (4.5%)	15.0 (6.5%)	28.0 (5.4%)	
	UNABLE TO OBTAIN	5.0 (1.7%)	4.0 (1.7%)	9.0 (1.7%)	
	UNKNOWN	36.0 (12.4%)	31.0 (13.4%)	67.0 (12.9%)	
	WHITE	187.0 (64.5%)	145.0 (62.8%)	332.0 (63.7%)	
Male Gender		166.0 (57.2%)	139.0 (60.2%)	305.0 (58.5%)	0.5002
OASIS Score		40.2 (8.7)	37.4 (8.8)	39.0 (8.9)	< 0.001 ¹
APSi Score		66.7 (25.9)	62.5 (24.9)	64.9 (25.5)	0.0591
SAPSi Score		46.9 (14.7)	44.3 (13.9)	45.7 (14.4)	0.0401
SOFA Score		9.7 (3.4)	9.2 (3.2)	9.5 (3.3)	0.1151
AIDS		6.0 (2.1%)	4.0 (1.7%)	10.0 (1.9%)	0.7802
CVD		37.0 (12.8%)	27.0 (11.7%)	64.0 (12.3%)	0.7122
COPD		88.0 (30.3%)	65.0 (28.1%)	153.0 (29.4%)	0.5832
CHF		70.0 (24.1%)	67.0 (29.0%)	137.0 (26.3%)	0.2102
Dementia		15.0 (5.2%)	15.0 (6.5%)	30.0 (5.8%)	0.5202
Diabetes with CC		24.0 (8.3%)	29.0 (12.6%)	53.0 (10.2%)	0.1092
Diabetes without CC		59.0 (20.3%)	47.0 (20.3%)	106.0 (20.3%)	1.0002
Malignant Cancer		61.0 (21.0%)	31.0 (13.4%)	92.0 (17.7%)	0.0242
Metastatic Solid Tumor		29.0 (10.0%)	16.0 (6.9%)	45.0 (8.6%)	0.2152
Mild Liver Disease		55.0 (19.0%)	29.0 (12.6%)	84.0 (16.1%)	0.0482
MI		46.0 (15.9%)	45.0 (19.5%)	91.0 (17.5%)	0.2802
Paraplegia		12.0 (4.1%)	11.0 (4.8%)	23.0 (4.4%)	0.7312
Peptic Ulcer Disease		16.0 (5.5%)	11.0 (4.8%)	27.0 (5.2%)	0.6992
PVD		33.0 (11.4%)	38.0 (16.5%)	71.0 (13.6%)	0.0942
Renal Disease		61.0 (21.0%)	61.0 (26.4%)	122.0 (23.4%)	0.1502
Rheumatic Disease		13.0 (4.5%)	10.0 (4.3%)	23.0 (4.4%)	0.9322
Severe Liver Disease		23.0 (7.9%)	18.0 (7.8%)	41.0 (7.9%)	0.9532
Weight		79.1 (22.2)	82.9 (21.8)	80.8 (22.1)	0.0491
Central Line		259.0 (74.6%)	95.0 (55.2%)	354.0 (68.2%)	< 0.001 ²
First Hospital Admission		210.0 (72.4%)	168.0 (72.7%)	378.0 (72.6%)	0.9372
First ICU Admission		271.0 (93.4%)	212.0 (91.8%)	483.0 (92.7%)	0.4662
Mechanically Ventilated prior to NE		180.0 (62.1%)	114.0 (49.4%)	294.0 (56.4%)	0.0042
Hospital LOS		15.2 (14.6)	15.1 (15.8)	15.2 (15.1)	0.9131
ICU LOS		6.5 (6.4)	5.1 (5.6)	5.9 (6.1)	0.0101
Mortality		59.0 (20.3%)	34.0 (14.7%)	93.0 (17.9%)	0.0962
Total Fluids		3337.9 (1569.1)	958.6 (551.3)	2283.0 (1703.7)	< 0.001 ¹
Fluids per Kg per Hour		3.5 (0.8)	3.6 (0.8)	3.5 (0.8)	0.1301
Fluids per Kg		42.9 (18.3)	11.9 (6.4)	29.2 (21.0)	< 0.001 ¹
		Late NE (N=110)	Early NE (N=117)	Total (N=227)	p value
Mechanical Ventilation after NE		23.0 (20.9%)	24.0 (20.5%)	47.0 (20.7%)	0.9412

Supplemental Table 7: Outcomes in Early and Late NE Groups within Quartile 3

Predictor	Estimate	SE	Z	p	Odds Ratio of Standardized Estimate	Lower	Upper
Mortality	0.014	0.291	0.047	0.962	1.014	0.573	1.794
Mechanical Ventilation	0.291	0.458	0.634	0.526	1.337	0.545	3.282
Hospital LOS	-0.238	1.266	-0.188	0.851	-0.008	-0.09	0.074
ICU LOS	-0.94	0.511	-1.841	0.066	-0.076	-0.158	0.005

Supplemental Table 8: Baseline Characteristics of Early and Late NE Groups in Patients Receiving Quartile 4 of Fluids (>5.075 mL/kg*hr)

		Late NE (N=134)	Early NE (N=383)	Total (N=517)	p value
Age		66.6 (16.3)	65.5 (16.0)	65.8 (16.1)	0.4631
Ethicity					0.1892
	ASIAN	9.0 (6.7%)	14.0 (3.7%)	23.0 (4.4%)	
	BLACK/AFRICAN AMERICAN	11.0 (8.2%)	34.0 (8.9%)	45.0 (8.7%)	
	HISPANIC/LATINO	7.0 (5.2%)	10.0 (2.6%)	17.0 (3.3%)	
	OTHER	5.0 (3.7%)	22.0 (5.7%)	27.0 (5.2%)	
	UNABLE TO OBTAIN	3.0 (2.2%)	6.0 (1.6%)	9.0 (1.7%)	
	UNKNOWN	6.0 (4.5%)	38.0 (9.9%)	44.0 (8.5%)	
	WHITE	93.0 (69.4%)	259.0 (67.6%)	352.0 (68.1%)	
Male Gender		69.0 (51.5%)	225.0 (58.7%)	294.0 (56.9%)	0.1442
OASIS Score		39.0 (9.4)	38.1 (9.9)	38.3 (9.8)	0.3271
APSiII Score		69.0 (29.8)	62.4 (24.3)	64.1 (26.0)	0.0121
SAPSiII Score		46.9 (15.5)	44.0 (14.9)	44.8 (15.1)	0.0551
SOFA Score		9.1 (3.3)	9.1 (3.2)	9.1 (3.2)	0.9291
AIDS		3.0 (2.2%)	4.0 (1.0%)	7.0 (1.4%)	0.3032
CVD		9.0 (6.7%)	38.0 (9.9%)	47.0 (9.1%)	0.2672
COPD		35.0 (26.1%)	104.0 (27.2%)	139.0 (26.9%)	0.8162
CHF		27.0 (20.1%)	105.0 (27.4%)	132.0 (25.5%)	0.0972
Dementia		5.0 (3.7%)	18.0 (4.7%)	23.0 (4.4%)	0.6402
Diabetes with CC		9.0 (6.7%)	37.0 (9.7%)	46.0 (8.9%)	0.3032
Diabetes without CC		23.0 (17.2%)	96.0 (25.1%)	119.0 (23.0%)	0.0612
Malignant Cancer		23.0 (17.2%)	71.0 (18.5%)	94.0 (18.2%)	0.7232
Metastatic Solid Tumor		10.0 (7.5%)	30.0 (7.8%)	40.0 (7.7%)	0.8902
Mild Liver Disease		14.0 (10.4%)	58.0 (15.1%)	72.0 (13.9%)	0.1772
MI		17.0 (12.7%)	67.0 (17.5%)	84.0 (16.2%)	0.1942
Paraplegia		12.0 (9.0%)	18.0 (4.7%)	30.0 (5.8%)	0.0702
Peptic Ulcer Disease		7.0 (5.2%)	24.0 (6.3%)	31.0 (6.0%)	0.6622
PVD		14.0 (10.4%)	45.0 (11.7%)	59.0 (11.4%)	0.6832
Renal Disease		23.0 (17.2%)	89.0 (23.2%)	112.0 (21.7%)	0.1422
Rheumatic Disease		7.0 (5.2%)	10.0 (2.6%)	17.0 (3.3%)	0.1442
Severe Liver Disease		3.0 (2.2%)	32.0 (8.4%)	35.0 (6.8%)	0.0152
Weight		68.2 (15.5)	76.8 (21.7)	74.6 (20.6)	< 0.001 ¹
Central Line		110.0 (82.1%)	191.0 (49.9%)	301.0 (58.2%)	< 0.001 ²
First Hospital Admission		94.0 (70.1%)	273.0 (71.3%)	367.0 (71.0%)	0.8042
First ICU Admission		128.0 (95.5%)	344.0 (89.8%)	472.0 (91.3%)	0.0442
Mechanically Ventilated prior to NE		74.0 (55.2%)	171.0 (44.6%)	245.0 (47.4%)	0.0352
Hospital LOS		14.5 (13.7)	20.1 (63.1)	18.7 (54.8)	0.3041
ICU LOS		6.4 (6.7)	6.5 (19.8)	6.5 (17.3)	0.9251
Mortality		27.0 (20.1%)	59.0 (15.4%)	86.0 (16.6%)	0.2042
Total Fluids		4756.6 (1908.1)	1742.9 (1377.5)	2524.0 (2022.5)	< 0.001 ¹
Fluids per Kg per Hour		7.4 (2.6)	19.5 (44.1)	16.4 (38.3)	0.0011
Fluids per Kg		71.5 (29.8)	23.9 (19.6)	36.2 (30.8)	< 0.001 ¹
		Late NE (N=60)	Early NE (N=212)	Total (N=272)	p value
Mechanical Ventilation after NE		11.0 (18.3%)	48.0 (22.6%)	59.0 (21.7%)	0.4752

Supplemental Table 9: Outcomes in Early and Late NE Groups within Quartile 4

Predictor	Estimate	SE	Z	p	Odds ratio	Lower	Upper
Mortality	-0.197	0.328	-0.599	0.549	0.821	0.432	1.564
Mechanical Ventilation	0.369	0.451	0.819	0.413	1.447	0.598	3.5
Hospital LOS	2.566	5.743	0.447	0.655	0.021	-0.07	0.111
ICU LOS	-0.072	1.832	-0.039	0.969	-0.002	-0.093	0.089